Bank of New York Mellon Corp Grows Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Bank of New York Mellon Corp lifted its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 6.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 671,966 shares of the company’s stock after purchasing an additional 38,487 shares during the period. Bank of New York Mellon Corp owned about 0.26% of Lyell Immunopharma worth $974,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC bought a new position in Lyell Immunopharma in the fourth quarter worth approximately $31,000. RPO LLC bought a new position in Lyell Immunopharma in the 4th quarter worth $38,000. Simplicity Wealth LLC purchased a new position in Lyell Immunopharma during the first quarter valued at $58,000. Jacobs Levy Equity Management Inc. bought a new stake in Lyell Immunopharma during the first quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Lyell Immunopharma by 67.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 48,855 shares of the company’s stock worth $109,000 after buying an additional 19,718 shares in the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Stock Down 3.2 %

NASDAQ:LYEL opened at $1.51 on Friday. The business’s 50-day simple moving average is $1.45 and its two-hundred day simple moving average is $1.98. Lyell Immunopharma, Inc. has a 52 week low of $1.09 and a 52 week high of $3.26. The stock has a market cap of $384.96 million, a PE ratio of -1.68 and a beta of -0.53.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. The company had revenue of $0.01 million for the quarter. Sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -0.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Bank of America lowered their price objective on Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, June 27th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research report on Monday, August 19th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.